​Sanofi Genzyme takes on world’s top-selling drugs with new approval

With Monday ’s announcement that U.S. regulators have approved a drug for rheumatoid arthritis developed by Sanofi Genzyme and Regeneron Pharmaceuticals, the two drugmakers revealed a tried-and-true strategy to take on the world’s number one and number three best-selling drugs, which also happen to be for t hat same disease: give it a lower price. Cambridge-based Sanofi Genzyme (NYSE: SNY) and Tarrytown, N.Y.-based Regeneron (NYSE: REGN) will market their new drug, which has the generic name of…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news